Overall, our data support the therapeutic potential of co-targeting the integrin/FAK-dependent pathway and the BRD4-associated epigenetic network for KRAS mutated NSCLC (Figure 7C). The gene discussed is KRAS; the disease is non-small cell lung carcinoma.